284 citations
,
November 1999 in “Neurology” This article discusses the side effects of interferon beta therapy for MS, including flu-like symptoms and autoimmune reactions, and provides guidance on their management but does not report new clinical findings.
37 citations
,
May 2004 in “Multiple Sclerosis Journal” This article highlights adverse skin reactions due to injectable therapies for MS, noting that while generally mild, some cases can progress to serious lesions requiring medical intervention.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” This review outlines strategies for preventing, identifying, and managing complications related to current MS therapies and reports no new clinical results, emphasizing the growing complexity in MS treatment regimens.
6 citations
,
March 2016 in “Multiple sclerosis and related disorders” This case report describes a 55-year-old woman who experienced transient hair loss possibly linked to the start of dimethyl-fumarate therapy for relapsing-remitting Multiple Sclerosis.
3 citations
,
July 2021 in “International journal of environmental research and public health/International journal of environmental research and public health” This study reports two cases of Alopecia Universalis as a secondary autoimmune manifestation following Alemtuzumab treatment, highlighting the importance of screening and monitoring for such autoimmune responses.